CATB - カタバシス・ファ―マシュ―ティカルズ （Catabasis Pharmaceuticals Inc.） カタバシス・ファ―マシュ―ティカルズCATBのチャート
CATBの企業情報
| symbol | CATB |
|---|---|
| 会社名 | Catabasis Pharmaceuticals Inc （カタバシス・ファ―マシュ―ティカルズ） |
| 分野（sector） | Health Care ヘルスケア |
| 産業（industry） | Major Pharmaceuticals |
| 業種 | バイオテクノロジ―_メディカルリサ―チ 医療関連（Health Care） |
| 概要 | 事業概要 Catabasis Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the discovery development and commercialization of therapeutics based on its Safely Metabolized And Rationally Targeted (SMART) a linker drug discovery platform. The SMART linker drug discovery platform enables to engineer product candidates that can modulate multiple targets in a disease. The Company's primary focus is on treatments for rare diseases. The Company is also developing other product candidates for the treatment of lipid disorders. The Company's CAT-1004 is a SMART linker conjugate of salicylate a non-steroidal anti-inflammatory drug and the omega-3 fatty acid docosahexaenoic acid (DHA) a naturally occurring unsaturated fatty acid with anti-inflammatory properties. Its CAT-2000 series product candidates inhibit the Sterol Regulatory Element Binding Protein (SREBP) pathway. The Company's CAT-4001 is a SMART linker conjugate of monomethyl fumarate and DHA. カタバシス・ファ―マシュ―ティカルズは米国の臨床段階のバイオ医薬品企業。同社独自の「SMART」技術に基づき、治療薬を開発、製造、販売する。この技術は、複数の関連疾患の経路に複数の生物学的タ―ゲットの組み合わせにより疾患を治療するのが狙い。同社は筋ジストロフィ―を治療する薬を扱う。本社はマサチュ―セッツ州。 |
| 本社所在地 | One Kendall Square Bldg. 1400E Suite B14202 Cambridge MA 02139 USA |
| 代表者氏名 | Kenneth M. Bate ケネス・ベイト |
| 代表者役職名 | Co-Chairman of the Board |
| 電話番号 | +1 617-349-1971 |
| 設立年月日 | 39600 |
| 市場名 | NASDAQ National Market System |
| ipoyear | 2015年 |
| 従業員数 | 36人 |
| url | www.catabasis.com |
| nasdaq_url | https://www.nasdaq.com/symbol/catb |
| adr_tso | ― |
| EBITDA | EBITDA（百万ドル） -26.44500 |
| 終値（lastsale） | 0.776 |
| 時価総額（marketcap） | 55125813.144 |
| 時価総額 | 時価総額（百万ドル） 49.12307 |
| 売上高 | 売上高（百万ドル） 0.50000 |
| 企業価値(EV) | 企業価値(EV)（百万ドル） 0.02307 |
| 当期純利益 | 当期純利益（百万ドル） -26.64500 |
| 決算概要 | 決算概要 BRIEF: For the six months ended 30 June 2018 Catabasis Pharmaceuticals Inc revenues was not reported. Net loss decreased 5% to $14.1M. Lower net loss reflects Interest expense decrease of 67% to $90K (expense) Other income net increase from $23K to $159K (income). Basic Earnings per Share excluding Extraordinary Items increased from -$0.73 to -$0.49. |
CATBのテクニカル分析
CATBのニュース
Catabasis Pharmaceuticals (NASDAQ:CATB) Releases Quarterly Earnings Results, Misses Estimates By $0.07 EPS 2021/03/13 00:20:07 Transcript Daily
Catabasis Pharmaceuticals (NASDAQ:CATB) announced its quarterly earnings results on Wednesday. The biotechnology company reported ($0.44) earnings per share for the quarter, missing the consensus estimate of ($0.37) by ($0.07), Fidelity Earnings reports. Catabasis Pharmaceuticals stock traded down $0.09 during mid-day trading on Friday, hitting $3.37. The company had a trading volume of 27,015 shares, compared […]
Catabasis Pharmaceuticals Reports Fourth Quarter and Full Year 2020 Financial Results and Provides a Corporate Update 2021/03/11 21:10:00 Business Wire
BOSTON--(BUSINESS WIRE)--Catabasis Pharmaceuticals Reports Fourth Quarter and Full Year 2020 Financial Results and Provides a Corporate Update
Catabasis Pharmaceuticals To Present At Upcoming Investor Conferences 2021/03/02 13:00:00 Business Wire
BOSTON--(BUSINESS WIRE)--Catabasis Pharmaceuticals To Present At Upcoming Investor Conferences.
Catabasis Pharmaceuticals Acquires Quellis Biosciences | FinSMEs 2021/02/01 09:31:35 FinSMEs
Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB), a biopharmaceutical company, acquired Quellis Biosciences, a biopharmaceutical company focused on discovering new molecules to treat serious rare diseases
88 Biggest Movers From Friday 2021/02/01 09:07:57 Benzinga
Gainers Siebert Financial Corp. (NASDAQ: SIEB ) shares climbed 121.6% to close at $8.22 on Friday on heavy volume. Catabasis Pharmaceuticals, Inc. (NASDAQ: CATB ) climbed 70.8% to close at $4.15 after the company announced the acquisition of Quellis Biosciences. GameStop Corp. (NYSE: GME ) shares added 67.9% to close at $325.00 after Robinhood said it would allow some buying of the stocks on Friday after sparking outrage over discontinuing purchases of GME, AMC, and high stocks seeing social media interest. The company’s stock dropped over 44% on Thursday. Novavax, Inc. (NASDAQ: NVAX ) surged 64.9% to close at $220.94 after the company said Thursday that its COVID-19 vaccine candidate NVX-COV2373 showed 89.3% efficacy in Phase 3 trials conducted in the United Kingdom. AMC Entertainment Holdings, Inc. (NYSE: AMC ) surged 53.7% to close at $13.26 after Robinhood said it would allow some buying of the stocks on Friday after sparking outrage over discontinuing purchases of GME, AMC, and high stocks seeing social media interest.
Catabasis Pharmaceuticals To Present At Upcoming Investor Conferences 2021/03/02 13:00:00 Business Wire
BOSTON--(BUSINESS WIRE)--Catabasis Pharmaceuticals To Present At Upcoming Investor Conferences.
Catabasis Pharmaceuticals Acquires Quellis Biosciences | FinSMEs 2021/02/01 09:31:35 FinSMEs
Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB), a biopharmaceutical company, acquired Quellis Biosciences, a biopharmaceutical company focused on discovering new molecules to treat serious rare diseases
88 Biggest Movers From Friday 2021/02/01 09:07:57 Benzinga
Gainers Siebert Financial Corp. (NASDAQ: SIEB ) shares climbed 121.6% to close at $8.22 on Friday on heavy volume. Catabasis Pharmaceuticals, Inc. (NASDAQ: CATB ) climbed 70.8% to close at $4.15 after the company announced the acquisition of Quellis Biosciences. GameStop Corp. (NYSE: GME ) shares added 67.9% to close at $325.00 after Robinhood said it would allow some buying of the stocks on Friday after sparking outrage over discontinuing purchases of GME, AMC, and high stocks seeing social media interest. The company’s stock dropped over 44% on Thursday. Novavax, Inc. (NASDAQ: NVAX ) surged 64.9% to close at $220.94 after the company said Thursday that its COVID-19 vaccine candidate NVX-COV2373 showed 89.3% efficacy in Phase 3 trials conducted in the United Kingdom. AMC Entertainment Holdings, Inc. (NYSE: AMC ) surged 53.7% to close at $13.26 after Robinhood said it would allow some buying of the stocks on Friday after sparking outrage over discontinuing purchases of GME, AMC, and high stocks seeing social media interest.
CATB Stock: Why Catabasis Pharma Stock Is Skyrocketing Today 2021/01/29 15:46:46 InvestorPlace
Catabasis Pharma (CATB) stock is soaring higher on Friday after announcing its acquisition of Quellis Biosciences and a PIPE.
Catabasis Pharmaceuticals snaps up HAE antibody in buyout; Gladstone, UCSF scientist spearhead launch of neuro research center 2021/01/29 15:30:38 Endpoints News
A few months after finally admitting defeat on their failed Duchenne MD program, Catabasis Pharmaceuticals is heading in a new direction with the purchase of Quellis Biosciences and their lead antibody for hereditary angioedema. Catabasis shared the news on Friday that they’re buying out Quellis, a rare disease-focused biotech that
Catabasis Pharmaceuticals: 9 Things for Potential CATB Stock Investors to Know 2020/12/02 17:12:30 InvestorPlace
Catabasis Pharmaceuticals (CATB) stock is taking off on Wednesday despite a lack of news from the biopharmaceutical company.
Catabasis Pharmaceuticals Reports Third Quarter 2020 Financial Results and Provides a Corporate Update 2020/11/12 21:10:00 Business Wire
BOSTON--(BUSINESS WIRE)--Catabasis Pharmaceuticals Reports Third Quarter 2020 Financial Results and Provides a Corporate Update
The Daily Biotech Pulse: Aurinia Pulls The Plug On Dry Eye Disease Study, Karyopharm's Positive Readout, Emergency Use Authorization For OraSure 2020/11/03 12:38:06 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Nov. 2) Bio-Rad Laboratories, Inc. Class A Common Stock (NYSE: BIO ) Immunovant Inc (NASDAQ: IMVT ) United Therapeutics Corporation (NASDAQ: UTHR ) Down In The Dumps (Biotech Stocks Hitting 52-week Lows Nov. 2) AEterna Zentaris Inc. (NASDAQ: AEZS ) Aikido Pharma Inc (NASDAQ: AIKI ) Artelo Biosciences Inc (NASDAQ: ARTL ) Avita Therapeutics Inc (NASDAQ: RCEL ) Benitec Biopharma Inc (NASDAQ: BNTC ) BioCardia Inc (NASDAQ: BCDA ) Biondvax Pharmaceuticals Ltd – ADR (NASDAQ: BVXV ) Catabasis Pharmaceuticals Inc (NASDAQ: CATB ) Celsion Corporation (NASDAQ: CLSN ) Codiak BioSciences Inc (NASDAQ: CDAK ) Cumberland Pharmaceuticals, Inc. (NASDAQ: CPIX ) Entasis Therapeutics Holdings Inc (NASDAQ: ETTX ) FSD Pharma Inc (NASDAQ: HUGE ) Galecto Inc (NASDAQ: GLTO ) (went public Thursday) Hoth Therapeutics Inc (NASDAQ: HOTH ) Inhibrx Inc (NASDAQ: INBX ) Iterum Therapeutics PLC (NASDAQ: ITRM ) Jaguar Health Inc (NASDAQ: JAGX ) Lexicon Pharmaceuticals, Inc. (NASDAQ: LXRX ) Monopar Therapeutics Inc (NASDAQ: MNPR ) Nabriva Therapeutics PLC – ADR (NASDAQ: NBRV ) Neovasc Inc (NASDAQ: NVCN ) Neurobo Pharmaceuticals Inc (NASDAQ: NRBO ) Orchard Therapeutics PLC – ADR (NASDAQ: ORTX ) (halted dosing in Strimvelis study after it was linked to the development of leukemia in a patient) Orphazyme A S ADR (NASDAQ: ORPH ) Pliant Therapeutics Inc (NASDAQ: PLRX ) RA Medical Systems Inc (NYSE: RMED ) Recro Pharma Inc (NASDAQ: REPH ) Rockwell Medical Inc (NASDAQ: RMTI ) Teligent Inc (NEW JERSEY) (NASDAQ: TLGT ) Titan Pharmaceuticals, Inc. common stock (NASDAQ: TTNP ) Stocks In Focus Aurinia Ends Dry Eye Disease Study Aurinia Pharmaceuticals Inc (NASDAQ: AUPH ) said topline results from its Phase 2/3 AUDREY clinical study evaluating voclosporin ophthalmic solution for the potential treatment of …
The Week Ahead In Biotech (Nov. 1-7): Adcom Test For Biogen's Aducanumab, Alzheimer's Conference, SMID-cap Earnings 2020/11/01 14:40:39 Benzinga
Biotech stocks continued to sway to the tunes of the broader market in the week ended Oct. 30, which succumbed to geopolitical and macroeconomic concerns. Several big-name pharma companies, including Merck & Co. Inc. (NYSE: MRK ) and Pfizer Inc. (NYSE: PFE ), reported earnings during the week. The earnings news flow was broadly mixed. Catabasis Pharmaceuticals Inc (NASDAQ: CATB ) was among the biggest decliners, as it halted a late-stage trial of its Duchenne muscular dystrophy drug. On the other hand, Scholar Rock Holding Corp. (NASDAQ: SRRK ) was up about over 175% during the week, reacting to positive mid-stage results for spinal muscular atrophy drug. On the COVID-19 front, Regeneron Pharmaceuticals Inc. said it is (NASDAQ: REGN ) halting the Phase 3 trial of its antibody cocktail in patients with severe COVID-19, citing safety issue. Kala Pharmaceuticals Inc. (NASDAQ: KALA ) announced FDA approval for its dry eye disease drug, while Spectrum Pharmaceuticals Inc. (NASDAQ: SPPI ) communicated a delay in the decision for its treatment option for chemotherapy-induced neutropenia, as the FDA could not inspect a plant in South Korea due to COVID-19.